These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32868327)

  • 1. Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
    Lê MP; Le Hingrat Q; Jaquet P; Wicky PH; Bunel V; Massias L; Visseaux B; Messika J; Descamps D; Mal H; Timsit JF; Peytavin G
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.
    Yan VC; Muller FL
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988821
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
    Lê MP; Le Beller C; Le Hingrat Q; Jaquet P; Wicky PH; Bunel V; Massias L; Visseaux B; Messika J; Descamps D; Mal H; Timsit JF; Peytavin G
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988815
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Remdesivir for COVID-19: Data to Date.
    Mehta M; Shyh GI
    Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
    Jorgensen SCJ; Kebriaei R; Dresser LD
    Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early experience with remdesivir in SARS-CoV-2 pneumonia.
    Durante-Mangoni E; Andini R; Bertolino L; Mele F; Florio LL; Murino P; Corcione A; Zampino R
    Infection; 2020 Oct; 48(5):779-782. PubMed ID: 32418190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Audio Interview: New Data on Remdesivir in Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
    [No Abstract]   [Full Text] [Related]  

  • 9. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
    Deb S; Reeves AA
    J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.
    Humeniuk R; Mathias A; Cao H; Osinusi A; Shen G; Chng E; Ling J; Vu A; German P
    Clin Transl Sci; 2020 Sep; 13(5):896-906. PubMed ID: 32589775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
    Goldman JD; Lye DCB; Hui DS; Marks KM; Bruno R; Montejano R; Spinner CD; Galli M; Ahn MY; Nahass RG; Chen YS; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wei X; Gaggar A; Brainard DM; Towner WJ; Muñoz J; Mullane KM; Marty FM; Tashima KT; Diaz G; Subramanian A;
    N Engl J Med; 2020 Nov; 383(19):1827-1837. PubMed ID: 32459919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report study of the first five COVID-19 patients treated with remdesivir in France.
    Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
    Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective.
    Mansuri Z; Shah B; Zafar MK; Jolly T; Jain S
    Prim Care Companion CNS Disord; 2020 May; 22(3):. PubMed ID: 32470232
    [No Abstract]   [Full Text] [Related]  

  • 14. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
    Aleissa MM; Silverman EA; Paredes Acosta LM; Nutt CT; Richterman A; Marty FM
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir for the Treatment of Covid-19 - Final Report.
    Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; Lopez de Castilla D; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC;
    N Engl J Med; 2020 Nov; 383(19):1813-1826. PubMed ID: 32445440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral treatment for COVID-19: the evidence supporting remdesivir.
    Richardson C; Bhagani S; Pollara G
    Clin Med (Lond); 2020 Nov; 20(6):e215-e217. PubMed ID: 32863273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver injury in remdesivir-treated COVID-19 patients.
    Zampino R; Mele F; Florio LL; Bertolino L; Andini R; Galdo M; De Rosa R; Corcione A; Durante-Mangoni E
    Hepatol Int; 2020 Sep; 14(5):881-883. PubMed ID: 32725454
    [No Abstract]   [Full Text] [Related]  

  • 19. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
    Sun D
    AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
    Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
    J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.